Expression of CD25 antigen on CD34+ cells is an independent predictor of outcome in late-stage MDS patients treated with azacitidine.

Blood Cancer J · 2014 · PMC3944665 · PMID 24583533

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

marginally statistically significantP =0.08so close (0.05 < p ≤ 0.1)

Three groups with different outcome were identified with marginally statistically significant median OS ( P =0.08) and EFS ( P =0.06), potentially because only 4 (7%) patients were stratified as low risk (data not shown), indicating, however, that despite its limited size, our patient sample was representative in comparison with the existing literature.

also in 1,110 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.